# Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

> **NCT01271283** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia

## Interventions

- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01271283
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271283, "Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01271283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*